Sibel Health raises $33mn in Series B funding and announces new executive appointments to scale advanced wearable sensors for remote patient monitoring and hospital care
Niles, United States. 04 August, 2022 – Sibel Health, an medical technology company spun out of the John Rogers Research Group and the Querrey Simpson Institute for Bioelectronics at Northwestern University, has recently closed a [$33 million (€32.33 million)] Series B financing round, bringing Sibel’s total funding to date to more than [$50 million (€48.98 million)].
In addition, Sibel has announced two new executive appointments. Jon Otterstatter, the former CEO and co-founder of Preventice (acquired by Boston Scientific in 2021), will join as chairman of the board. Matthew Banet, PhD, a expert in advanced body-worn sensors and previously the CTO and cofounder of toSense and Sotera, joins as president from Baxter International.
The funding round was led by the Steele Foundation for Hope – a private foundation seeking to fund solutions for humanity’s hardest challenges with an emphasis on technology and innovation. Joe Exner, CEO of Steele Foundation for Hope, says “Sibel was founded by the world’s leading engineers and scientists. We invested in their ingenuity to advance bio-integrated sensors and wireless data collection to promote better care, especially for mothers and newborns in developing countries.” Dräger, a medical and safety technology company, previous convertible note changes to equity.
With the funding, Sibel will scale up its FDA-cleared ANNE One platform for global deployments across the entire continuum of care from the home to the hospital. “What makes us unique as a digital health company is that our product is vertically integrated – we believe that everything matters, from the adhesive we place on the skin to how the sensor fits on the body to the final alert a clinician sees for medical decision-making,” says Steve Xu, MD, CEO and co-founder. “We’re proud that our technology can be potentially deployed in both the neonatal intensive care unit and in the home for remote patient monitoring.”
Steffen Protsch, president of monitoring at Dräger and Sibel board member, says “As an early investor in Sibel, we have been impressed by the company’s growth and technology over such a short period of time. We look forward to integrating and scaling their technology as part of Dräger’s offerings to our hospital customers.”
Since 2020, Sibel has seen a significant increase in revenue driven by partnerships with Fortune 500 companies and funding support from the U.S. military, the National Institutes of Health, and the Bill & Melinda Gates Foundation. The appointment of new executives will accelerate Sibel’s transition to scaled commercialisation.
“I look forward to joining Sibel as chairman of the board in this time of rapid acceleration and growth,” Otterstatter, says “The company’s advanced wearable monitoring platform is industry-changing – the comprehensive suite of on-body sensors, best-in-class analytics, robust machine-learning algorithms and extensible software capabilities make the ANNE One platform a very unique offering. I look forward to supporting Sibel’s transition towards commercial scale.” He continues, “Having led a team and a company that successfully developed and achieved commercial success with a breakthrough remote cardiac monitoring solutions, I am convinced that the ANNE sensors are raising the bar for the market.” John Rogers, PhD, the Louis Simpson and Kimberly Querrey Professor of Materials Science and Engineering at Northwestern University and Sibel co-founder, says “It is exciting to see the research from my research group translate into a successful product with the potential to impact millions of lives worldwide, particularly in the area of neonatal and women’s health.”
Comment on this article below or via Twitter @IoTGN